In a unanimous decision, the Fifth Circuit overturned an FDA rule allowing the mailing of abortion pills, reinstating a prior rule requiring them to be dispensed in-person.
Attorneys from multiple states contended that mailing procedures circumvented state laws restricting abortions and that prescriptions were to be filled in person or at a clinic only.
"By enabling the delivery of mifepristone through such an arrangement, this regulation provides an effective means of placing the drug in the hands of Louisianans despite their state law prohibition," Circuit Judge Kyle Duncan of the Fifth Circuit ruled.
Supreme Court will hear arguments on the ban
Following the request of Danco Laboratories, a producer of the pills, the Supreme Court on Saturday sought to restore mail deliveries of the pill, potentially leading to what could be one of the most significant Supreme Court rulings concerning abortion rights since Dobbs v. Jackson Women’s Health Organization, which overturned the right to abortion and returned it to the jurisdiction of state governments.
With the Roe v. Wade overturning, approximately 25 percent of all abortions have been performed using telemedicine. If the Supreme Court upholds the injunction, the procedure will become even harder to access.
“This action is alarming in light of the court’s willingness to disregard scientific facts and the FDA’s decades of experience approving and monitoring the safety of mifepristone when used under its labeled indication by people across the country and in this particular case at the hands of abortion extremists,” said Evan Masingill, CEO of GenBioPro, one of the mifepristone manufacturers.
As per data provided by the Guttmacher Institute, about 63 percent of abortions in states without bans were medication abortions in 2023. The percentage was even higher in some rural states, like Wyoming (95 percent), and Montana (84 percent).
The widespread use of this form of abortion has made mifepristone an easy target for opponents of abortions following the Roe decision. Mifepristone, one of the two drugs used for the most widely used type of medical abortion, has been on the market since 2000 following approval from the Food and Drug Administration. The Supreme Court had previously upheld mifepristone's legality in 2024.
The FDA has been defending the drug from safety concerns for the past two decades, and scientific findings have shown that it aborts pregnancies in 99.6 percent of cases.
Democrats' response to newly established protections
In response to the repeal of access to abortions in many states as per the Dobbs decision, Democrat-dominated states established shield laws to provide protection to abortionists who prescribed pills via telemedicine and delivered them to women living in states that banned abortion.
There are multiple states controlled by Republicans where attorneys general are planning to prevent access to such a procedure. It remains unknown how the upcoming Supreme Court's decision would affect telemedicine abortion bans in Idaho, Kansas and Missouri. Florida and Texas plan to prohibit mifepristone.
It should be noted that the Department of Health and Human Services, headed by Robert F. Kennedy Jr., who served in the Trump administration, conducts an ongoing review of mifepristone-related federal regulations. In response to that, the FDA requested to stop the case pending a full review of regulations. The request was granted by a district court, and the decision effectively prevented any change in access to the abortion pill. Louisiana immediately filed an appeal and sent the case to the Fifth Circuit Court of Appeals.
According to the American Civil Liberties Union, the ongoing HHS review is a thinly veiled effort to "lay the groundwork" for future medical restrictions on abortions.
Post a Comment